TY - JOUR
T1 - Efficacy and Safety of Palbociclib Plus Endocrine Therapy in Black and Hispanic Patients with Hormone Receptor Positive/human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer (HR+/HER2- ABC) Participating in the PALOMA Trials
AU - Mahtani, Reshma
N1 - Abstract. Background: The PALOMA clinical trials have shown that palbociclib (PAL) plus endocrine therapy (ET) is a safe and effective treatment for HR+/HER2- ABC. However, Black and Hispanic patients are underrepresented in clinical trials and the efficacy and safety of CDK4/6 inhibitors in these populations have not been reported.
PY - 2022/2/15
Y1 - 2022/2/15
N2 - C. Isaacs, F. Lynce, B. Sleckman, A. Castrellon, S. Kalmadi, K. Theall, X. Huang, E. Bananis, H. Rugo.
AB - C. Isaacs, F. Lynce, B. Sleckman, A. Castrellon, S. Kalmadi, K. Theall, X. Huang, E. Bananis, H. Rugo.
UR - https://aacrjournals.org/cancerres/article/82/4_Supplement/P1-18-13/680517
M3 - Article
VL - 82
JO - Cancer Research / San Antonio Breast Cancer Symposium
JF - Cancer Research / San Antonio Breast Cancer Symposium
ER -